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A retrospective study was conducted to assess the efficacy of D-penicillamine in the manage-
ment of cystinuria, as well as to define the frequency and nature of untoward reactions to this
drug. Fifty-six individuals were identified who, by stone analysis and/or biochemical studies,
met the accepted diagnostic criteria for phenotypic cystinuria. The majority of these patients
presented in the second decade oflife with evidence ofstone formation: renal colic, hematuria,
and/or stone passage. Thirty-five individuals were considered to have clinically advanced
cystinuria because they had required at least one urinary tract lithotomy. In these advanced
cases, frequency ofsubsequent lithotomies and episodes of renal colic per 100 patient-years of
observation were used as indices to measure the efficacy ofD-penicillamine treatment. By both
measurements, D-penicillamine significantly improved the clinical course of patients. The in-
cidence ofacute drug sensitivity reactions (rash, fever, and/or arthropathy) was in excess of40
percent. Delayed drug-induced proteinuria occurred in 34 percent of treated patients. We con-
clude that D-penicillamine is useful in the treatment of cystinuria. Because of the significant
number of untoward drug reactions, however, we believe the drug should be instituted only in
selected, high-risk patients.
INTRODUCTION
Cystinuria, a disorder of cystine and dibasic amino acid transport, is inherited as
an autosomal recessive trait. The transport defect affects the epithelial cells of the
renal tubules and the mucosa of the small intestine. Because of the renal defect, an
excessive quantity of cystine, the least soluble of the naturally occurring amino
acids, is present in the urine. This predisposes to the formation of renal, ureteral,
and bladder calculi composed of cystine. The major causes of morbidity and mor-
tality in this disorder are the sequellae of stone formation: renal and ureteral colic,
urinary tract infection, obstruction, and compromise of renal function. There are
several recent comprehensive reviews of cystinuria [1-3].
Patients with cystinuria are treated primarily with large quantities oforal fluids to
reduce the concentration of cystine in the urine. Therapy may also include urinary
alkalinizing agents since the solubility of cystine increases significantly above urine
pH 7.5 [4]. Several years ago experiments showed that cystine, which is readily
crystallized from the urine of cystinuric subjects, could not be crystallized from the
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All rights of reproduction in any form reserved.same urines after the addition of D-penicillamine in vitro [5]. This phenomenon
depends on a thiol-disulfide exchange reaction that forms a penicillamine-cysteine
disulfide 50 times more soluble than cystine [6]. Oral consumption of one to two
grams of D-penicillamine per day, in divided doses, has been shown to reduce
urinary cystine concentration, stabilize stone disease, and even dissolve existing
stones [5,7,8]. In the treatment of cystinuria, therefore, fluid ingestion is frequently
combined with urinary alkalinizing agents and/or D-penicillamine. We have under-
taken a study to define more clearly the efficacy of and untoward reactions to
D-penicillamine in the management of cystinuria.
MATERIALS AND METHODS
Patient Selection
Medical records were retrieved from six medical centers in the northeastern
United States for all patients with the diagnosis of cystinuria during the years 1940
to 1978.1 From this group, we identified 56 patients who met one or more ofthe gen-
erally accepted diagnostic criteria for cystinuria: (a) cystine stone removed at surgery
or passed spontaneously; (b) chemical analysis of urine demonstrating excessive ex-
cretion of cystine and dibasic amino acids; (c) positive urine nitroprusside test [8];
and (d) cystine crystalluria.
Clinical Evaluation
Data on age at presentation, sex, race, and presenting symptoms were recorded.
Clinical progress was evaluated from hospital history and clinic notes, reports of
intravenous pyelograms and abdominal X-rays, and reports ofurologic surgical pro-
cedures. Events scored included: (a) urinary tract lithotomy (nephrolithotomy,
ureterolithotomy, nephrectomy for stone disease, and cystolithotomy); and (b)
episodes of presumed renal colic associated with X-ray findings demonstrating a
stone, passage of a stone, or finding a stone at surgery.
It was necessary to select comparable groups of D-penicillamine-treated and
D-penicillamine-untreated patients to test the efficacy of the drug. In our review of
medical records, we found that the most commonly cited indication for D-penicil-
lamine use was the failure of more conservative measures (such as fluid administra-
tion) to control the disease. A simple comparison of D-penicillamine-treated versus
D-penicillamine-untreated groups would, therefore, introduce a systematic bias
because D-penicillamine is usually prescribed in more advanced cases. To select a
more comparable population ofclinically advanced cases, we used an initial urinary
tract lithotomy as the signal event to enter a patient into the study. We make the
assumption that the surgical event denotes relatively severe disease. Since therapy
preceding the lithotomy did not affect entrance into the study, we accept some varia-
tion in severity of disease within the study group. Operative procedures, as a signal
event, have the advantage of easy identification in medical histories. Thirty-five of
the 56 patients had such a surgical procedure.
Patient-years of observation following the operation were used as the denomi-
nator for the events scored in these 35 patients. This provided an index to evaluate
the efficacy of D-penicillamine in relatively advanced cystinuria. Statistical
significance was evaluated by chi-square analysis [9,101.
'Children's Hospital of Philadelphia, Coney Island Hospital, Hospital of the University of Pennsyl-
vania, Massachusetts General Hospital, West Haven Veteran's Administration Hospital (Connecticut),
Yale-New Haven Hospital.
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Treatment Modalities
Three forms of medical treatment were distinguished. First, treatment with oral
fluids consisted of instructing the patient to consume large volumes of water or
other fluids routinely. Patients were instructed to drink so as to never feel thirst, and
in amounts adequate to require voiding at least once each night. Second, treatment
to promote urinary alkalinization consisted ofinstructing the patient to ingest, at in-
tervals throughout the day, sodium bicarbonate or sodium citrate solution and, in
some cases, acetazolamide at bedtime. Third, D-penicillamine treatment consisted
of oral administration of one to two grams of the drug per day in divided doses.
Documented evidence or narrative report of non-compliance with a treatment pro-
gram prompted exclusion of the patient-years of observation in question. An at-
tempt was made to employ D-penicillamine as a component of therapy in 32 of the
total population of 56 patients (57 percent) and in 24 of the subgroup of 35 patients
(69 percent) who had undergone a lithotomy. In the tabulation of episodes of
lithotomy or renal colic, an individual patient could contribute to the D-penicil-
lamine treatment and D-penicillamine non-treatment groups if, for example, the
drug was instituted and then withdrawn.
Evaluation ofSide Effects
In the 32 patients who received D-penicillamine at some time during treatment,
note was made of untoward reaction(s) attributed to the drug. Note was also made
of whether or not the side effect necessitated withdrawal of the drug.
RESULTS
Characteristics ofthe Population
Data from the medical records of 56 individuals who met one or more of the
generally accepted diagnostic criteria of cystinuria are presented in Table 1. Each
criterion would, on its own, be sufficient to make the diagnosis. In this group the
diagnosis of cystinuria was generally made by stone or gravel analysis and/or urine
TABLE I
Diagnostic Criteria for Phenotypic Cystinuria in 56 Patients
Patients for whom this
was the only criterion
Criteria Number Percent Number Percent
Cystine stone (removed 51 91 4 7
at surgery or passed
spontaneously)
Urinary cytine excretion 33 59 2 4
greater than 400 mg/
day or 250 mg/g of
creatinine
Positive nitroprusside test 29 52 1 2
Paper chromatographic 23 41 0 0
electrophoresis show-
ing excessive excretion
of cystine and dibasic
amino acids
Cystine crystalluria 17 30 1 2
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TABLE 2
Population Characteristics of 56 Cystinuric Patients
Patients Percent
Sex
Male 29 52
Female 27 48
Race
Caucasian 44 79
Black 3 5
Unknown 9 16
chemical assays. For 48/56 patients (86 percent), the diagnosis was supported by
several other criteria. Conversely, few (14 percent) of our patients had the diagnosis
made by a single criterion. A near equal sex distribution was found (Table 2). In the
47 patients where race was known, Caucasians were predominant.
The reasons for clinical presentation are shown in Table 3. Most patients sought
medical attention with the well-known signs of nephrolithiasis: renal colic,
hematuria, stone passage, recurrent urinary tract infections, and back pain. A sur-
prisingly large number ofpatients (20 percent) were discovered while asymptomatic.
Chemical or microscopic urinalysis, usually undertaken as a screening measure in
relatives of a patient with cystinuria, was used to make the diagnosis in these pa-
tients. Mean age at onset of first symptom (excluding asymptomatic patients identi-
fied by routine screening) was 17.4 + 9.9 years for males and 19.5 8.4 years for
females. The mean age of diagnosis of the asymptomatic patients was 19.8 + 10.9
years.
Efficacy ofD-Penicillamine
The data in Table 4 show that patients with clinically advanced cystinuria on treat-
ment programs that included D-penicilliamine required significantly less urinary
tract surgery for stone removal than did patients on treatment programs that did not
include the drug. The findings demonstrate, moreover, that D-penicillamine treat-
TABLE 3
Presenting Medical Problems in 56 Patients with Cystinuria
Number Percent*
Renal colic 28 50
Hematuria 11 20
Asymptomatic** 11 20
Stone passage 7 13
Recurrent urinary tract
infections 5 9
Back pain 3 5
Anuria 2 4
*Total is greater than 100 percent because some patients had
more than one presenting complaint.
**No urinary tract symptoms. The diagnosis was made by:
screening relatives of a cystinuric patient, 9; routine urinalysis,
.1; urine biochemical tests done during evaluation of a mentally
retarded child, 1.
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TABLE 4
Frequency of Subsequent Urinary Tract Lithotomy and Renal Colic in 35 Patients with Cystinuria*
Number of Operations Number of
Treatment Patient- Lithotomy per 100 Episodes of Episodes per 100
Modality Years Operations Patient-Years Renal Colic Patient-Years
Fluids or 210.5 28 13.3 53 25.1
Fluids/Alkali
p < 0.01 p < 0.05
Fluids/
D-penicillamine
or
Fluids/Alkali/ 114.7 2 1.7 16 13.19
D-penicillamine
*All patients had undergone at least one surgical procedure for stone removal prior to inclusion in this
study.
ment programs significantly reduced episodes of renal colic. The decrease-from
25.1 episodes/100 patient-years in the D-penicillamine untreated group to 13.9 in the
D-penicillamine treated group-is significant at the p = 0.05 level. Although one
might speculate that the institution of penicillamine in a patient with stones would
temporarily increase the attacks ofcolic as dissolving stones are passed, we observed
no such tendency.
Side Effects ofD-Penicillamine
Thirty-two of our 56 patients were treated with D-penicillamine sometime during
the course of their illness. Side effects attributed to the drug are detailed in Table 5.
Rash, fever, pruritus, and arthropathy were common early side effects. The usual
interval from initiation ofthe drug to manifestation ofeach ofthese four side effects
was nine to ten days. Late onset untoward reactions included proteinuria and abnor-
malities of taste and smell. Proteinuria (greater than 500 mg/24 hr) occurred in 34
percent of the patients with a median time to onset, after initiation of the drug, of
five months. Proteinuria occurred as early as one month following initiation of
D-penicillamine and as late as 45 months after instituting the drug. The three epi-
sodes of abnormalities of taste and smell occurred one to two months after the drug
was begun.
Eighteen of the initial 32 attempts to treat patients with D-penicillamine were
halted because of side effects (56 percent). Institution of and maintenance on the
TABLE 5
Side Effects of D-Penicillamine in 32 Patients with Cystinuria
Side Effect Number Percent
Rash 14 44
Fever* 12 38
Proteinuria** 11 34
Pruritus 7 22
Arthropathy 5 16
Abnormalities of taste/smell 3 9
*Greater than99.60 po or 100.3° pr; not associated with infec-
tion
**Greater than 500 mg/24 hr
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drug for a period of one year or more was eventually achieved in eight of these 18
patients. Overall, D-penicillamine therapy was known to have been instituted and
maintained for a period of one year or more in 17 of the 32 patients (53 percent).
DISCUSSION
In the initial 1810 case report describing the condition now known as cystinuria,
the diagnosis was based on stone analysis [11]. Currently, the diagnosis of the
disease continues to rest most often on stone or crystal analysis. In addition, the
diagnosis can be made by urine chemical studies. Our population of cystinuric pa-
tients is similar to that reported from the Mayo Clinic [121 in that quantitative urine
cystine measurements and/or stone analysis were the principal means ofestablishing
the diagnosis. The two groups differ in that more patients in our series had the
diagnosis supported by several diagnostic tests.
Except for three Blacks, all patients in whom race was known were Caucasian
(Table 2). Cystinuria has been reported rarely in Blacks and Orientals [13,141. Our
finding of an equal sex distribution is expected for this autosomal recessive trait.
Males have been alleged to be more severely affected-perhaps due to the greater
likelihood of urethral obstruction [2]. The recent Mayo Clinic study, however,
found that the morbidity and severity ofcystinuria were not significantly different in
men and women [12]. Our finding that the median age at presentation for males and
females was 17.3 and 19.6 years, respectively, agrees with other published experience
[1,12].
Thepresenting signs and symptoms ofcystinuria arethose common to most forms
of urolithiasis: gross hematuria, renal colic with or without stone passage, urinary
tract infection, and back pain (Table 3). A substantial percentage of our patients
with cystinuria (20 percent) were discovered as a result of screening-usually con-
ducted among relatives of affected individuals. Screening has not generally been
reported as an important method ofidentifying affected individuals. It may become
more important in coming years as population screening becomes more widely
employed. It will be interesting to study these asymptomatic individuals to learn if
early institution of therapy changes the natural history of the disease.
Following initial reports ofthe usefulness ofD-penicillamine in human cystinuria,
there have been descriptions of the ability of the drug to "dissolve" clinically impor-
tant stones, and to stabilize or improve the course of the disease [5-8,12]. Unfortu-
nately, there has never been a controlled trial of the therapeutic efficacy of
D-penicillamine in cystinuria. The low incidence ofcystinuria (- 1:10,000) makes it
unlikely that such a study will ever be done. To date, the most careful clinical
evaluation of the role ofD-penicillaminein cystinuriahasbeenreported by Dahlberg
and his colleagues at the Mayo Clinic [12]. Utilizing measurements of"metabolic ac-
tivity" of stone disease-that is an assessment of "active," "inactive," or "indeter-
minate activity" of disease based on X-ray changes or gravel passage [15]-the
authors analyzed data from 54 patients. Thirty patients were treated with fluids and
alkali alone and became "metabolically inactive." On the other hand, 15 of the 24
patients in the D-penicillamine-treated group experienced dissolution of calculi or
significant reduction in stone size.
In our patient population, the use of measurements of "metabolic activity" was
impractical because of variability in the detail, availability, and frequency of X-ray
reports of stone size and changes. In addition, there was insufficient documentation
to allow the use offrequency ofurinary tract infections or episodes ofstone passage
as indices. Fortunately, lithotomy procedures and hospital or office visits for renal
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colic associated with a stone are generally well documented and useful indices of
clinical progress. Because we found that the institution of D-penicillamine was most
often undertaken because of the failure of more conservative measures in an in-
dividual patient, we believe that a systematic bias is introduced if one simply com-
pares D-penicillamine treatment programs to those that did not include the drug. We
attempted to avoid this bias by limiting our analysis to patient-years of observation
following an initial lithotomy-a sub-population of more "severely" affected in-
dividuals.
In the selected population of "severely" affected cystinuric patients, treatment
programs which included D-penicillamine significantly reduced the frequency of
renal colic and lithotomy surgery (Table 4). It thus appears that penicillamine can
modify in a favorable way the natural history of cystinuria. Although we can give no
assurance of equal compliance to all treatment programs, we have no reason to
believe that addition of D-penicillamine to treatment programs altered compliance
with hydration as the principal therapeutic modality.
A substantial literature is accumulating on the side effects of D-penicillamine
[3,16-18]. The reported toxic effects include: sensitivity reactions of the serum-
sickness sort, hematologic dysfunction including leukopenia, agranulocytosis, and
thrombocytopenia; taste and smell abnormalities; nephrotoxicity manifested as pro-
teinuria, nephrotic syndrome, or a rapidly progressive glomerulonephritis; and
nausea and epigastric distress. About 40 percent of our aptients (Table 5) developed
serum sickness evidenced by rash, fever, pruritus, and/or arthropathy. Even more
distressing is our observation that about one-third of the D-penicillamine-treated pa-
tients developed significant proteinuria. In none, however, did this progress to the
nephrotic syndrome.
Proteinuria caused by D-penicillamine resolved, in all cases, when the drug was
stopped. Reinstitution of the drug, at conventional doses, was generally followed by
recurrence of proteinuria. In our experience, reinstitution of the drug by a "desen-
sitization" regimen is best for avoiding recurrence of proteinuria and other side ef-
fects. The "desensitization" technique utilizes initial doses of D-penicillamine of 10
to 25 mg/day. The dose is raised slowly, at three-day intervals, until a dose of1 to
1.5 gm/day is reached after approximately 30 days.
The Mayo Clinic series of 43 cystinuric patients who received D-penicillamine dif-
fered from our group in the reported frequency of side effects [12]. The Mayo Clinic
group was subject to fewer episodes of rash with fever or lymphadenopathy (28 per-
cent), abnormalities of taste or smell (14 percent), or "high grade" proteinuria (9 per-
cent). One patient had drug-related granulocytopenia. We have no explanation for
the lower incidence of side effects in the Mayo Clinic Study.
The side effects of D-penicillamine in 33 patients with Wilson's Disease have also
been reported [191. Rash, fever, and/or adenopathy occurred in 48 percent of the
patients. Ecchymosis, particularly at pressure points, was reported in 18 percent of
the group. Leucopenia or thrombocytopenia was an untoward effect in 24 percent.
None developed significant proteinuria. The variation in the frequency and distribu-
tion of side effects related to D-penicillamine in patients with cystinuria and
Wilson's Disease may be ascribed to dose variation, duration of use, the patient's
general medical condition, and, possibly, to differences in the antigenicity of the
drug in various disease states.
D-penicillamine has been shown to be a useful adjunct in the treatment of
cystinuria. Because of the dangers of D-penicillamine therapy, however, we recom-
mend that it be used only if fluids and urinary alkalinization have been unsuccessful,
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or ifthe patient has already lost one kidney from stone disease. Drugs that may pro-
vide an alternative to D-penicillamine in the management of cystinuria are currently
under investigation [20-22].
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